Cargando…

Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer

Circulating tumor DNA (ctDNA) is increasingly being investigated as a tool to detect minimal residual disease in resected, stage I-III colorectal cancer. Recent ctDNA studies have indicated that detection of ctDNA following surgery for resectable colorectal cancer confers a significantly higher risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Jun, Aguirre, Francesca, Hazelett, Dennis, Alvarez, Rocio, Zhou, Lisa, Hendifar, Andrew, Osipov, Arsen, Zaghiyan, Karen, Cho, May, Gangi, Alexandra, Hitchins, Megan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022091/ https://www.ncbi.nlm.nih.gov/pubmed/35463213 http://dx.doi.org/10.3892/mco.2022.2533

Ejemplares similares

POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval
por: Bikhchandani, Mihir, et al.
Publicado: (2023)

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer
por: Gong, Jun, et al.
Publicado: (2021)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
por: Lee, Patrick C., et al.
Publicado: (2021)

Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
por: Vogelaar, Ingrid P., et al.
Publicado: (2022)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021)

A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer
por: Anderson, Eric, et al.
Publicado: (2021)

Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
por: Midthun, Lauren, et al.
Publicado: (2022)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

Pancreatic cancer ‘mismatch’ in Lynch syndrome
por: Hendifar, Andrew E, et al.
Publicado: (2019)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma
por: Hendifar, Andrew, et al.
Publicado: (2016)

Gut microbiome and pancreatic cancer cachexia: An evolving relationship
por: Hendifar, Andrew, et al.
Publicado: (2022)

The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report
por: Judge, Sean J., et al.
Publicado: (2020)

Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
por: Qureshi, Naveen, et al.
Publicado: (2023)

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
por: Osipov, Arsen, et al.
Publicado: (2019)

Methylated Septin9 (mSEPT9): A Promising Blood-Based Biomarker for the Detection and Screening of Early-Onset Colorectal Cancer
por: Loomans-Kropp, Holli A., et al.
Publicado: (2022)

Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer
por: Muranaka, Hayato, et al.
Publicado: (2023)

Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
por: Gong, Jun, et al.
Publicado: (2023)

Methylated SEPTIN9 plasma test for colorectal cancer detection may be applicable to Lynch syndrome
por: Hitchins, Megan P, et al.
Publicado: (2019)

Chemotherapy-associated liver injury in colorectal cancer
por: Gangi, Alexandra, et al.
Publicado: (2020)

Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma
por: Gong, Jun, et al.
Publicado: (2020)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry
por: Ward, Robyn L., et al.
Publicado: (2013)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
por: Kim, Jeong Yeon, et al.
Publicado: (2020)

Impact of postoperative telemedicine visit versus in-person visit on patient satisfaction: A randomized clinical trial
por: Yao, Lucille Y., et al.
Publicado: (2023)

Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient‐reported outcomes in pancreatic cancer cachexia
por: Gresham, Gillian, et al.
Publicado: (2021)

Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000–2018
por: Samaan, Jamil S., et al.
Publicado: (2023)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Immunotherapy for Colorectal Cancer
por: Boland, Patrick M., et al.
Publicado: (2017)

The role of MYH and microsatellite instability in the development of sporadic colorectal cancer
por: Colebatch, A, et al.
Publicado: (2006)

Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
por: C. Huynh, Jasmine, et al.
Publicado: (2020)

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy
por: Kim, Sungjin, et al.
Publicado: (2020)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Expert opinions on immunotherapy for patients with colorectal cancer
por: Wang, Feng, et al.
Publicado: (2020)

Diagnostic and therapeutic potential of RNASET2 in Crohn’s disease: Disease-risk polymorphism modulates allelic-imbalance in expression and circulating protein levels and recombinant-RNASET2 attenuates pro-inflammatory cytokine secretion
por: Biener-Ramanujan, Eva, et al.
Publicado: (2022)

Affinity Density: a novel genomic approach to the identification of transcription factor regulatory targets
por: Hazelett, Dennis J., et al.
Publicado: (2009)

motifbreakR: an R/Bioconductor package for predicting variant effects at transcription factor binding sites
por: Coetzee, Simon G., et al.
Publicado: (2015)

Circulating Concentrations of C-Peptide and Colorectal Adenoma
por: Choi, Yoon Ji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9huegmel479fiunuqbugsd4g9r